Leap Therapeutics, Inc. LPTX
Apr 1, 2026, 9:30 AM EDT
52-week range unavailable
- YTD
- -73.28%
- 1 year
- -76.32%
- Market cap
- 110.74M
- Shares out
- 38.32M
- Forward P/E
- -2.31
- YTD return
- -73.28%
- 1-year return
- -76.32%
- Volume
- 848.47K
- Open
- 0.7645
- Previous close
- 0.7696
- Day's range
- 0.7351 – 0.7971
- Beta
- 0.22
- Price target
- 11.38 (+1378.0%)
2Y +0.20 (+12.82%)
Key statistics
- Enterprise value
- 32.59M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -30.07M
- Total cash
- 78.48M
- Total debt
- 482.00K
- Return on equity
- -80.54%
- Short % of float
- 3.13%
- 50-day average
- 3.07
- 200-day average
- 2.66
Analyst view
- Target (low)
- 5.50
- Target (mean)
- 11.38
- Target (high)
- 16.00
- Strong buy3
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.38333.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.46 | -0.44 | +0.02 | +4.35% |
| Aug 12, 2024 | Jun 1, 2024 | -0.42 | -0.52 | -0.10 | -23.81% |
| May 13, 2024 | Mar 1, 2024 | -0.57 | -0.51 | +0.06 | +10.53% |
| Mar 18, 2024 | Dec 1, 2023 | -0.56 | -0.46 | +0.10 | +17.86% |
| Nov 13, 2023 | Sep 1, 2023 | -0.48 | -0.51 | -0.03 | -6.25% |
| Aug 14, 2023 | Jun 1, 2023 | -0.98 | -0.91 | +0.07 | +7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 28, 2024 | Rodman & Renshaw | init | — | Buy |
| May 14, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 19, 2024 | Baird | main | Outperform | Outperform |
| Mar 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Leap Therapeutics, Inc.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- leaptx.com
News
Leap Therapeutics (NASDAQ:LPTX) vs. Panbela Therapeutics (OTCMKTS:PBLA) Head-To-Head Analysis 
Leap Therapeutics (NASDAQ:LPTX) and Nemus Bioscience (OTCMKTS:NMUS) Critical Contrast 
Contrasting Leap Therapeutics (NASDAQ:LPTX) and UCB (OTCMKTS:UCBJF) 
Reviewing Leap Therapeutics (NASDAQ:LPTX) and Vincerx Pharma (NASDAQ:VINC) 
Analyzing PaxMedica (NASDAQ:PXMD) and Leap Therapeutics (NASDAQ:LPTX) 
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Crude Oil Dips 4%; On Holding Shares Jump After Q3 Earnings - 12 Health Care Stocks Moving In Wednesday's Intraday Session
Dow Jumps More Than 400 Points; IHS Holding Posts Upbeat Q3 Results 
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Your note
Sign in to keep a note on LPTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAVANAUGH JAMES H | Director | Conversion of Exercise of derivative security | Nov 12, 2024 | 262,053 |
| LAWLOR AUGUSTINE | Chief Operating Officer | Conversion of Exercise of derivative security | Nov 12, 2024 | 0 |
| MIRABELLI CHRISTOPHER K | Chairman of the Board | Conversion of Exercise of derivative security | Nov 12, 2024 | 0 |
| O'MAHONY JOHN MARK | Officer | Conversion of Exercise of derivative security | Jan 25, 2024 | 5,000 |
| ONSI DOUGLAS E | Chief Executive Officer | Conversion of Exercise of derivative security | Nov 12, 2024 | 0 |
| SIRARD CYNTHIA M.D. | Officer | Conversion of Exercise of derivative security | Jan 25, 2024 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Balyasny Asset Management LLC | 8.05% | 3,085,104 | 8.92M | Sep 29, 2024 |
| Samsara BioCapital, LLC | 6.37% | 2,442,352 | 7.06M | Sep 29, 2024 |
| 683 Capital Management LLC | 3.60% | 1,380,500 | 3.99M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 3.31% | 1,266,546 | 3.66M | Sep 29, 2024 |
| Baker Bros. Advisors, LP | 3.06% | 1,172,175 | 3.39M | Sep 29, 2024 |
| Simplify Asset Management, Inc. | 2.76% | 1,056,895 | 3.05M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Simplify Exchange Traded Fds-Health Care ETF | 2.76% | 1,056,895 | 3.05M | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 1.97% | 754,737 | 2.18M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.69% | 262,807 | 759.51K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.45% | 172,542 | 498.65K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 68,981 | 199.35K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.15% | 56,092 | 162.10K | Oct 30, 2024 |